Bio-Techne Debt-to-Equity Ratio Growth & History (TECH)
Bio-Techne's debt-to-equity ratio was 0.14 for fiscal 2026.
View full Bio-Techne company overviewBio-Techne annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-06-30 | 0.14 | −0.09 | −40.75% |
| 2025 | 2025-06-30 | 0.23 | 0.03 | +14.12% |
| 2024 | 2024-06-30 | 0.20 | −0.03 | −12.35% |
| 2023 | 2023-06-30 | 0.23 | 0.05 | +25.60% |
| 2022 | 2022-06-30 | 0.18 | −0.08 | −29.44% |
| 2021 | 2021-06-30 | 0.26 | −0.04 | −14.35% |
| 2020 | 2020-06-30 | 0.30 | −0.12 | −27.88% |
| 2019 | 2019-06-30 | 0.42 | 0.11 | +34.54% |
| 2018 | 2018-06-30 | 0.31 | −0.05 | −13.22% |
| 2017 | 2017-06-30 | 0.36 | 0.26 | +247.87% |
| 2016 | 2016-06-30 | 0.10 | 0.02 | +20.73% |
| 2015 | 2015-06-30 | 0.09 | 0.09 | — |
| 2014 | 2014-06-30 | 0.00 | — | — |
Bio-Techne quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-06-30 | 0.14 | −0.09 | −40.75% |
| Q3 2026 | 2026-03-31 | 0.14 | −0.07 | −33.66% |
| Q2 2026 | 2025-12-31 | 0.17 | −0.02 | −8.21% |
| Q1 2026 | 2025-09-30 | 0.20 | 0.01 | +7.58% |
| Q4 2025 | 2025-06-30 | 0.23 | 0.03 | +14.12% |
| Q3 2025 | 2025-03-31 | 0.21 | −0.04 | −14.55% |
| Q2 2025 | 2024-12-31 | 0.19 | −0.09 | −32.83% |
| Q1 2025 | 2024-09-30 | 0.19 | −0.09 | −32.19% |
| Q4 2024 | 2024-06-30 | 0.20 | −0.03 | −12.35% |
| Q3 2024 | 2024-03-31 | 0.25 | −0.01 | −2.09% |
| Q2 2024 | 2023-12-31 | 0.28 | 0.12 | +78.82% |
| Q1 2024 | 2023-09-30 | 0.28 | 0.08 | +41.04% |
| Q4 2023 | 2023-06-30 | 0.23 | 0.05 | +25.60% |
| Q3 2023 | 2023-03-31 | 0.25 | 0.07 | +36.63% |
| Q2 2023 | 2022-12-31 | 0.16 | −0.04 | −20.53% |
| Q1 2023 | 2022-09-30 | 0.20 | −0.03 | −12.35% |
| Q4 2022 | 2022-06-30 | 0.18 | −0.08 | −29.44% |
| Q3 2022 | 2022-03-31 | 0.18 | 0.00 | +0.88% |
| Q2 2022 | 2021-12-31 | 0.20 | 0.01 | +3.58% |
| Q1 2022 | 2021-09-30 | 0.22 | −0.05 | −17.14% |
| Q4 2021 | 2021-06-30 | 0.26 | −0.04 | −14.35% |
| Q3 2021 | 2021-03-31 | 0.18 | −0.19 | −51.69% |
| Q2 2021 | 2020-12-31 | 0.19 | −0.15 | −43.65% |
| Q1 2021 | 2020-09-30 | 0.27 | −0.20 | −43.25% |
| Q4 2020 | 2020-06-30 | 0.30 | −0.12 | −27.88% |
| Q3 2020 | 2020-03-31 | 0.38 | −0.07 | −15.30% |
| Q2 2020 | 2019-12-31 | 0.34 | −0.14 | −29.79% |
| Q1 2020 | 2019-09-30 | 0.47 | −0.02 | −4.36% |
| Q4 2019 | 2019-06-30 | 0.42 | 0.11 | +34.54% |
| Q3 2019 | 2019-03-31 | 0.44 | 0.07 | +19.91% |
| Q2 2019 | 2018-12-31 | 0.49 | 0.12 | +33.78% |
| Q1 2019 | 2018-09-30 | 0.49 | 0.14 | +40.76% |
| Q4 2018 | 2018-06-30 | 0.31 | −0.05 | −13.22% |
| Q3 2018 | 2018-03-31 | 0.37 | −0.01 | −2.01% |
| Q2 2018 | 2017-12-31 | 0.36 | −0.02 | −5.85% |
| Q1 2018 | 2017-09-30 | 0.35 | −0.03 | −8.37% |
| Q4 2017 | 2017-06-30 | 0.36 | 0.26 | +247.87% |
| Q3 2017 | 2017-03-31 | 0.38 | 0.19 | +104.57% |
| Q2 2017 | 2016-12-31 | 0.39 | 0.20 | +102.99% |
| Q1 2017 | 2016-09-30 | 0.38 | 0.19 | +95.58% |
| Q4 2016 | 2016-06-30 | 0.10 | 0.02 | +20.73% |
| Q3 2016 | 2016-03-31 | 0.19 | 0.01 | +5.36% |
| Q2 2016 | 2015-12-31 | 0.19 | 0.01 | +8.34% |
| Q1 2016 | 2015-09-30 | 0.20 | 0.05 | +38.96% |
| Q4 2015 | 2015-06-30 | 0.09 | 0.09 | — |
| Q3 2015 | 2015-03-31 | 0.18 | — | — |
| Q2 2015 | 2014-12-31 | 0.18 | — | — |
| Q1 2015 | 2014-09-30 | 0.14 | — | — |
| Q4 2014 | 2014-06-30 | 0.00 | — | — |
Bio-Techne debt-to-equity ratio trends
Over the last five fiscal years, Bio-Techne's debt-to-equity ratio decreased from 0.26 to 0.14, a change of −0.12. The latest reported quarter, Q4 2026, shows 0.14.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bio-Techne source filings ↗